Figure 7
AML in patients less than 60 years of age. Survival, by karyotype, of de novo and therapy-related (t-AML) AML. MRC/NCRI AML Trials: overall survival. Adapted from Grimwade and Hills10 with permission.
AML in patients less than 60 years of age. Survival, by karyotype, of de novo and therapy-related (t-AML) AML. MRC/NCRI AML Trials: overall survival. Adapted from Grimwade and Hills10 with permission.
